High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV - but HIV viremia matters?

AIDS. 2022 Jul 15;36(9):1319-1320. doi: 10.1097/QAD.0000000000003239.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antibodies, Viral
  • BNT162 Vaccine
  • COVID-19 Vaccines
  • COVID-19* / prevention & control
  • HIV Infections*
  • Humans
  • RNA, Messenger
  • SARS-CoV-2
  • Seroconversion
  • Vaccination
  • Viremia

Substances

  • Antibodies, Viral
  • COVID-19 Vaccines
  • RNA, Messenger
  • BNT162 Vaccine